The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.

Details

Ressource 1Download: BIB_0DF65F1D66D1.P001.pdf (369.45 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_0DF65F1D66D1
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Journal
Blood Reviews
Author(s)
Kaiser-Guignard J., Canellini G., Lion N., Abonnenc M., Osselaer J.C., Tissot J.D.
ISSN
1532-1681 (Electronic)
ISSN-L
0268-960X
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
28
Number
6
Pages
235-241
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish Document Type: Review
Abstract
Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA-UVB (MIRASOL PRT), and UVC (Theraflex-UV). We review the biology of pathogen inactivation methods, present their efficacy in reducing pathogens, discuss their impact on the functional aspects of treated platelets, and review clinical studies showing the clinical efficiency of the pathogen inactivation methods and their possible toxicity.
Pubmed
Web of science
Open Access
Yes
Create date
02/01/2015 9:36
Last modification date
20/08/2019 12:35
Usage data